Best Practices in the Diagnosis and Treatment of Inflammatory Breast Cancer
Inflammatory breast cancer signs and symptoms mimic mastitis. Many physicians do not recognize that mastitis is common in younger, premenopausal women but uncommon in the post-menopausal population. The rarity of inflammatory breast cancer compared with the frequency of mastitis or cellulitis of the breast often results in a delay of a cancer work-up in favor of treating mastitis. This delay may affect the patient’s clinical course thus increasing the possibility of symptomatic spread of breast cancer and associated outcomes.
The webinar will review the clinical presentation of inflammatory breast cancer, discuss the NCCN guidelines for inflammatory breast cancer, and best practices for early diagnosis by primary care physicians, Ob-Gyn specialists, and advance practice providers.
- Primary care providers
- Ob-Gyn specialists
- Advance practice providers
- NAPBC Centers
- Patient Advocacy Organizations
- Describe the common presentation of inflammatory breast cancer and the characteristics that differentiate it from locally advanced disease.
- Identify best practice options for the timely diagnosis of inflammatory breast cancer.
- Discuss the NCCN guidelines for inflammatory breast cancer and compare the differences to the guidelines for non-inflammatory invasive breast cancer.
- For questions about the course, please contact NAPBC@facs.org.
- If you have any technical questions, contact firstname.lastname@example.org.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program/planning/editorial committee and authors complete disclosure forms. Individuals were required to disclose all financial relationships. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity. For additional information, please visit the ACCME website: http://www.accme.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions/financial-relationships-and-conflicts-interest
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias. The planning/editorial committee members and authors were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias, please advise us of the circumstances on the evaluation form.
The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.
Presenter and Disclosures
Beth Overmoyer, MD, FACS - nothing to disclose
Internal Medicine and Hematology and Oncology Hospital
University of Pennsylvania
Dr. Beth Overmoyer is a national and international expert on inflammatory breast cancer. She is currently the director of the Inflammatory Breast Cancer (IBC) Program at Dana-Farber Cancer Institute, which is one of three dedicated programs in the USA focusing on the care of patients with IBC. Dr. Overmoyer received her MD from Case Western Reserve School of Medicine followed by training in Internal Medicine and Hematology and Oncology at the Hospital of the University of Pennsylvania. She became the director of breast cancer research under the Case Comprehensive Cancer Center in Cleveland prior to joining Dana Farber. In addition to publishing extensively on IBC, she has been the principal investigator of several clinical trials designed specifically for IBC and oversees the translational research that result from these studies.
- 1.00 AMA PRA Category 1 Credit™